Lundbeck boosted by stockpiling, launches key drug remotely
Share:
COPENHAGEN (Reuters) - Danish drugmaker Lundbeck beat first-quarter sales expectations on Tuesday as distributors and patients stocked up on medicines amid lockdowns to contain the coronavirus pandemic.The company also said the U.S. launch of recently-acquired migraine drug eptinezumab, branded as Vyepti in the United States, had largely been a success, despite lockdowns forcing sales teams to switch from meetings with doctors to online contact. "In a launch perspective, we've largely been as..